Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 35 recruiting now early-phase tilt

Peripheral Arterial Disease: early-phase trial registry

35 of 80 indexed Peripheral Arterial Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #173 of 28,707 conditions by registered trial count.

80 US clinical trials · 35 currently recruiting · #173 of 28,707 conditions by registered trial count

Peripheral Arterial Disease: 80 US clinical trials tracked, 35 recruiting.

Peripheral Arterial Disease is the subject of 80 registered US clinical trials on ClinicalTrials.gov, 35 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is University of Nebraska, running 7 of these trials.

Enrollment posture brief

Registry condition peripheral-arterial-disease

OPEN 35 | RECR 44% | LATE 7 | EARLY 14 | RANK #173 | SPON 7

Nearest open-share peer: Acute Respiratory Distress Syndrome (44% recruiting · 32 trials)

Small-cell Lung Cancer47.5%Stage IV Lung Cancer AJCC v845.1%Peripheral Arterial Dise (th…44%Small Lymphocytic Lymphoma43.9%Liver Cancer37%
Open-enrollment share among volume-matched conditions near Peripheral Arterial Disease

Peripheral Arterial Disease lists 35 open slots (44% of 80 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Peripheral Arterial Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Peripheral Arterial Disease is recruiting above its size-band peers.

    35 of 80 indexed trials (43.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Peripheral Arterial Disease trials is spread across many organizations.

    University of Nebraska accounts for 7 of 80 trials (8.8%). 56 distinct sponsors appear on at least one study for this condition label.

  3. Typical Peripheral Arterial Disease enrolment sits around 100 participants.

    Median target enrolment is 100 among the 80 trials that report a genuine target (sentinel values excluded). 40 of those (50%) plan for fewer than 100 participants.

  4. Peripheral Arterial Disease research is mostly interventional.

    62 interventional and 18 observational studies make up this index (77.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 19Phase 25Phase 33Phase 44

Open and recent trials

80 total, page 2 of 2

COMPLETED NA 174 participants

Motivational Interviewing (MI) for African Americans With Peripheral Arterial Disease (PAD)

University of Kansas Medical Center

NCT01321086

COMPLETED 161 participants

Validation of a Novel Oscillometric-Based Algorithm for Determination of the Ankle-Brachial Index

Summit Doppler Systems

NCT01165437

COMPLETED NA 130 participants

A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)

ReFlow Medical

NCT05358353

COMPLETED NA 116 participants

Implementation of Telemedicine for Patient With Lower Extremity Wounds

University of California, Davis

NCT04440839

COMPLETED NA 112 participants

The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee

Horizons International Peripheral Group

NCT02464501

COMPLETED NA 108 participants

EverFlex Post Approval Study

Medtronic Endovascular

NCT01680835

COMPLETED NA 108 participants

A Prospective, Multicenter Atherectomy Study Showing Luminal Gain in Subjects With Peripheral Vascular Blockages

Ra Medical Systems

NCT04241224

COMPLETED 100 participants

Distributed Registry

Stanford University

NCT03898570

COMPLETED Phase 2 86 participants

Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia

Vericel Corporation

NCT00468000

COMPLETED 82 participants

TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions

Spectranetics Corporation

NCT03306199

COMPLETED Phase 1 81 participants

A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation

Indiana University

NCT02685098

COMPLETED 70 participants

Pilot Study to Determine the Optimal Technique for Measurement of Ankle Blood Pressures

Summit Doppler Systems

NCT00819598

COMPLETED Phase 4 55 participants

The Jetstream G3™ Calcium Study

Boston Scientific Corporation

NCT01273623

COMPLETED 40 participants

VasoStat vs. TR Band for Radial Hemostasis

Forge Medical

NCT04163471

COMPLETED Phase 2 32 participants

Nitrites, Exercise, and Peripheral Arterial Disease

Duke University

NCT01684930

COMPLETED NA 27 participants

Local Paclitaxel Delivery for SFA Disease

University of Oklahoma

NCT00821028

COMPLETED NA 24 participants

Ischemic Preconditioning Claudication Study

Medical College of Wisconsin

NCT03511157

COMPLETED NA 22 participants

Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy After Femoropopliteal Revascularization

University of California, San Francisco

NCT01507558

COMPLETED NA 22 participants

Cardiac Rehabilitation Program in Peripheral Arterial Disease

University of Kansas Medical Center

NCT03251391

COMPLETED Phase 1 20 participants

ALD-301 for Critical Limb Ischemia, Randomized Trial

Aldagen

NCT00392509

COMPLETED NA 19 participants

Endothelial Function in Lower Extremity Bypass Grafts

Brigham and Women's Hospital

NCT00759707

COMPLETED NA 18 participants

Exercise and Weight Loss in PAD

VA Office of Research and Development

NCT02607033

COMPLETED Phase 1 15 participants

Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU

Celularity Incorporated

NCT01859117

COMPLETED NA 15 participants

Drug Eluting Stent for the Management of PERipheral Arterial Disease Of the SFA (DESPERADO-SFA Study)

Arkansas Heart Hospital

NCT02734836

COMPLETED NA 12 participants

Feasibility Study to Evaluate Therapeutic Ultrasound (TUS) to Acutely Increase the Perfusion in Peripheral Arterial Disease (PAD)

Vibrato Medical

NCT05888740

COMPLETED NA 11 participants

Dietary Nitrate Supplementation and Thermoregulation

University of Nebraska

NCT03506646

COMPLETED Early Phase 1 10 participants

Safety and Preliminary Efficacy of Adipose Derived Stem Cells and Low Frequency Ultrasound in PAD

Arkansas Heart Hospital

NCT02756884

COMPLETED Phase 1 9 participants

Natural Vascular Scaffold (NVS) Therapy for Treatment of Atherosclerotic Lesions (Activate I)

Alucent Biomedical

NCT04188262

COMPLETED NA 8 participants

The Use of Fish Oil to Reduce Inflammation Caused by a Peripheral Vascular Intervention

University of California, San Francisco

NCT02096757

COMPLETED NA 5 participants

BOLD MRI as a Surrogate of Improved Muscle Oxygenation Following Endovascular Therapy for the Treatment of CLI

Zimmer Biomet

NCT02601430

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 9
Phase 2 5
Phase 3 3
Phase 4 4

Named interventions

Most-linked intervention names on Peripheral Arterial Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
Atherectomy Device
2 trials
Plain (Uncoated) Balloon Angioplasty (PTA) Device
2 trials
Jetstream Atherectomy System Device
1 trials
BOLD-MRI Other
1 trials
Bare Temporary Spur Stent System Device
1 trials
Optical Coherence Tomography Other
1 trials
Blood Pressure Measurement Procedure
1 trials

US sites by state

Facility locations filed on Peripheral Arterial Disease trials. A trial with sites in several states counts in each.

California 24 trials
Illinois 21 trials
Florida 20 trials
Texas 16 trials
Michigan 16 trials
Connecticut 14 trials
North Carolina 12 trials
Tennessee 11 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Peripheral Arterial Disease page

80 registered trials, 35 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 35 Peripheral Arterial Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • University of Nebraska sponsors the most Peripheral Arterial Disease trials on record, review their full trial history before evaluating a specific study. See University of Nebraska's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Peripheral Arterial Disease condition card totals 80 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.